Holistic artificial intelligence-driven predictor in HER2-positive (HER2+) early breast cancer (BC) treated with neoadjuvant lapatinib and trastuzumab without chemotherapy: A correlative analysis from SOLTI-1114 PAMELA

Battistella, Enzo & Paré Brunet, Laia & Sahasrabudhe, Mihir & Pascual, Tomás & Vakalopoulou, Maria & Villagrasa, Patricia & Deutsch, Eric & Chic, Nuria & Villacampa Javierre, Guillermo & Nuciforo, Paolo & Cortes, Javier & Llombart-Cussac, Antonio & Paragios, Nikos & Prat, Aleix

Year: 2021丨Publisher: Cancer Research

Stay posted

Sign up to receive the latest Therapanacea news!



    FR Office
    7 bis boulevard Bourdon
    75004, Paris – France
    mail @ therapanacea.eu

    Newsletter
    Get our latest news.

    Newsletter
    Demo
    Book a demo

    Privacy Preference Center